Ahmed Rizwan, Bae Sunjae, Hicks Caitlin W, Orandi Babak J, Atallah Chady, Chow Eric K, Massie Allan B, Lopez Joseph, Higgins Robert S, Segev Dorry L
Division of Plastics and Reconstructive Surgery, Duke University Medical Center, Durham NC.
Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD.
Ann Thorac Surg. 2017 Feb;103(2):567-572. doi: 10.1016/j.athoracsur.2016.06.053. Epub 2016 Jun 25.
The Physician Payment Sunshine Act was implemented to provide transparency to financial transactions between industry and physicians. Under this law, the Open Payments Program (OPP) was created to publicly disclose all transactions and inform patients of potential conflicts of interest. Collaboration between industry and cardiothoracic surgeon-scientists is essential in developing new approaches to treating patients with cardiac disease. The objective of this study is to characterize industry payments to cardiothoracic surgeons as reported by the OPP.
We used the first wave of Physician Payment Sunshine Act data (August 2013 to December 2013) to assess industry payments made to cardiothoracic surgeons.
Cardiothoracic surgeons (n = 2,495) received a total of $4,417,545 during a 5-month period. Cardiothoracic surgeons comprised 0.5% of all persons in the OPP and received 0.9% of total disclosed industry funding. Among cardiothoracic surgeons receiving funding, 34% received payments less than $100, 43% received payments of $100 to $999, 19% received payments of $1,000 to $9,999, 4% received payments of $10,000 to $99,999, and 0.2% received payments of more than $100,000. The median was $181 (interquartile range [IQR]: $60 to $843) and the mean ± SD was $1,771 ± $7,664. The largest payment to an individual surgeon was $159,444. The three largest median payments made to cardiothoracic surgeons by expense category were royalty fees $8,398 (IQR: $536 to $12,316), speaker fees $3,600 (IQR: $1,500 to $8,000), and honoraria $3,344 (IQR: $1,563 to $7,350).
Among cardiothoracic surgeons who are listed as recipients of nonresearch industry payments, 50% of cardiothoracic surgeons received less than $181. Awareness of the OPP data is critical for cardiothoracic surgeons, as it provides a means to prevent potential public misconceptions about industry payments within the specialty that may affect patient trust.
《医师薪酬阳光法案》的实施旨在提高行业与医师之间财务交易的透明度。根据该法律，设立了公开支付计划（OPP），以公开披露所有交易，并告知患者潜在的利益冲突。行业与心胸外科医生 - 科学家之间的合作对于开发治疗心脏病患者的新方法至关重要。本研究的目的是描述公开支付计划所报告的行业向心胸外科医生支付的款项情况。
我们使用了《医师薪酬阳光法案》的首批数据（2013年8月至2013年12月）来评估行业向心胸外科医生支付的款项。
在5个月期间，心胸外科医生（n = 2495）共收到4,417,545美元。心胸外科医生占公开支付计划中所有人员的0.5%，并获得了公开披露的行业资金总额的0.9%。在获得资金的心胸外科医生中，34%收到的款项少于100美元，43%收到的款项为100至999美元，19%收到的款项为1000至9999美元，4%收到的款项为10,000至99,999美元，0.2%收到的款项超过100,000美元。中位数为181美元（四分位间距[IQR]：60至843美元），均值±标准差为1,771±7,664美元。向单个外科医生支付的最大款项为159,4,44美元。按费用类别向心胸外科医生支付的中位数最高的三项分别是版税8,398美元（IQR：536至12,316美元）、演讲费3,600美元（IQR：1,500至8,000美元）和酬金3,344美元（IQR：1,563至7,350美元）。
在被列为非研究行业付款接收者的心胸外科医生中，50%的心胸外科医生收到的款项少于181美元。了解公开支付计划数据对心胸外科医生至关重要，因为它提供了一种手段，可防止该专业领域内公众对行业付款可能影响患者信任的潜在误解。
